TNF and rheumatoid arthritis: In the prevaccination period, as observed in patients with RA, patients with PsA treated with non-TNF-i-targeted therapy showed a modest, although statistically significant, reduction in DAS28 with respect to those treated with TNF-i (−0.107±0.031, p<0.001) (table 5).